CGH
CYTK icon

Crossmark Global Holdings’s Cytokinetics CYTK Stock Holding History

Crossmark Global Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$760K Buy
8,923
+275
+3% +$19.7K 0.01% 729
2026
Q1 		$570K Buy
8,648
+486
+6% +$30.9K 0.01% 787
2025
Q4 		$519K Buy
8,162
+347
+4% +$21.6K 0.01% 818
2025
Q3 		$430K Buy
7,815
+60
+0.8% +$2.47K 0.01% 954
2025
Q2 		$256K Buy
7,755
+174
+2% +$6.05K ﹤0.01% 1170
2025
Q1 		$305K Sell
7,581
-46
-0.6% -$2.11K 0.01% 1079
2024
Q4 		$359K Sell
7,627
-13
-0.2% -$675 0.01% 974
2024
Q3 		$403K Buy
7,640
+1,072
+16% +$59.8K 0.01% 956
2024
Q2 		$356K Sell
6,568
-8
-0.1% -$483 0.01% 979
2024
Q1 		$461K Sell
6,576
-890
-12% -$68.8K 0.01% 907
2023
Q4 		$623K Sell
7,466
-603
-7% -$21.8K 0.01% 756
2023
Q3 		$282K Buy
8,069
+19
+0.2% +$633 0.01% 1044
2023
Q2 		$268K Sell
8,050
-39
-0.5% -$1.44K 0.01% 1120
2023
Q1 		$284K Buy
8,089
+19
+0.2% +$775 0.01% 1067
2022
Q4 		$370K Sell
8,070
-120
-1% -$5.16K 0.01% 931
2022
Q3 		$397K Buy
8,190
+490
+6% +$23.6K 0.01% 867
2022
Q2 		$302K Sell
7,700
-170
-2% -$6.84K 0.01% 1022
2022
Q1 		$290K Buy
7,870
+20
+0.3% +$711 0.01% 1148
2021
Q4 		$358K Sell
7,850
-8,200
-51% -$316K 0.01% 1066
2021
Q3 		$574K Sell
16,050
-30
-0.2% -$883 0.01% 852
2021
Q2 		$318K Buy
16,080
+130
+0.8% +$3.05K 0.01% 1148
2021
Q1 		$371K Buy
15,950
+610
+4% +$13K 0.01% 1063
2020
Q4 		$319K Buy
+15,340
New +$280K 0.01% 1058
2017
Q4 		– Sell
-21,460
Closed -$311K – 1654
2017
Q3 		$311K Buy
+21,460
New +$293K 0.01% 1291
2016
Q3 		$311K Buy
+21,460
New +$224K 0.01% 1291

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crossmark Global Holdings's CYTK Position: Q2 2026 in Review

Crossmark Global Holdings increased its Cytokinetics (CYTK) stake by 3.2% in Q2 2026, buying an estimated $19.7K and bringing the position to 8,923 shares worth $760K. The position accounts for 0.01% of the portfolio, ranked #729.

Crossmark Global Holdings first reported a position in CYTK in Q3 2016 and has held it in 25 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Crossmark Global Holdings held 8,923 shares of Cytokinetics worth $760K as of Q2 2026.
  • Crossmark Global Holdings bought 275 Cytokinetics shares in Q2 2026, an estimated $19.7K.
  • Cytokinetics made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #729 holding.
  • Crossmark Global Holdings first reported a position in Cytokinetics in Q3 2016 and has held it in 25 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.